

# EMEA (Europe, Middle East and Africa) Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

<https://marketpublishers.com/r/E2478E83ACCEN.html>

Date: August 2017

Pages: 117

Price: US\$ 4,000.00 (Single User License)

ID: E2478E83ACCEN

## Abstracts

In this report, the EMEA Pulmonary Arterial Hypertension (PAH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs for these regions, from 2012 to 2022 (forecast)

Europe: Germany, France, UK, Russia, Italy and Benelux;

Middle East: Saudi Arabia, Israel, UAE and Iran;

Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Pulmonary Arterial Hypertension (PAH) Drugs market competition by top manufacturers/players, with Pulmonary Arterial Hypertension (PAH) Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

Actelion Pharmaceuticals

DAIICHI SANKYO

GlaxoSmithKline

Novartis

United Therapeutics

AADi

Actelion Pharmaceuticals

Aires Pharmaceuticals

Arena Pharmaceuticals

Asklepion Pharmaceuticals

AstraZeneca

Bayer Healthcare

Berlin Cures

BIAL

Eiger BioPharmaceuticals

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

Inhalation

Injectables

Oral administration

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs for each application,

including

ERAs

Prostacyclin analogs

PDE inhibitors

sGC stimulators

## Contents

EMEA (Europe, Middle East and Africa) Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

### **1 PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS OVERVIEW**

1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) Drugs

1.2 Classification of Pulmonary Arterial Hypertension (PAH) Drugs

1.2.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Sales) Comparison by Type (2012-2022)

1.2.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016

1.2.3 Inhalation

1.2.4 Injectables

1.2.5 Oral administration

1.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market by Application/End Users

1.3.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022)

1.3.2 ERAs

1.3.3 Prostacyclin analogs

1.3.4 PDE inhibitors

1.3.5 sGC stimulators

1.4 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market by Region

1.4.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Value) Comparison by Region (2012-2022)

1.4.2 Europe Status and Prospect (2012-2022)

1.4.3 Middle East Status and Prospect (2012-2022)

1.4.4 Africa Status and Prospect (2012-2022)

1.5 EMEA Market Size (Value and Volume) of Pulmonary Arterial Hypertension (PAH) Drugs (2012-2022)

1.5.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2022)

1.5.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2022)

### **2 EMEA PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION**

## 2.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Competition by Players/Manufacturers

2.1.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Market Share of Major Players (2012-2017)

2.1.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Share by Players (2012-2017)

2.1.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sale Price by Players (2012-2017)

## 2.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs (Volume and Value) by Type/Product Category

2.2.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type (2012-2017)

2.2.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Type (2012-2017)

2.2.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sale Price by Type (2012-2017)

## 2.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs (Volume) by Application

## 2.4 EMEA Pulmonary Arterial Hypertension (PAH) Drugs (Volume and Value) by Region

2.4.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Region (2012-2017)

2.4.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Region (2012-2017)

2.4.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Region (2012-2017)

# **3 EUROPE PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION**

## 3.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales and Value (2012-2017)

3.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Growth Rate (2012-2017)

3.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2017)

## 3.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type

## 3.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by

## Application

### 3.4 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Value (Revenue) by Countries

#### 3.4.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Countries (2012-2017)

#### 3.4.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2012-2017)

#### 3.4.3 Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

#### 3.4.4 France Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

#### 3.4.5 UK Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

#### 3.4.6 Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

#### 3.4.7 Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

#### 3.4.8 Benelux Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

## **4 MIDDLE EAST PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION**

### 4.1 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales and Value (2012-2017)

#### 4.1.1 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Growth Rate (2012-2017)

#### 4.1.2 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2017)

### 4.2 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type

### 4.3 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Application

### 4.4 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Value (Revenue) by Countries

#### 4.4.1 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Countries (2012-2017)

#### 4.4.2 Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2012-2017)

4.4.3 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

4.4.4 Israel Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

4.4.5 UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

4.4.6 Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

## **5 AFRICA PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION**

5.1 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Value (2012-2017)

5.1.1 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Growth Rate (2012-2017)

5.1.2 Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2017)

5.2 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type

5.3 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Application

5.4 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Value (Revenue) by Countries

5.4.1 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume by Countries (2012-2017)

5.4.2 Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2012-2017)

5.4.3 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

5.4.4 Nigeria Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

5.4.5 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

5.4.6 Algeria Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2012-2017)

## **6 EMEA PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA**

## 6.1 Actelion Pharmaceuticals

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

## 6.2 DAIICHI SANKYO

6.2.1 Company Basic Information, Manufacturing Base and Competitors

6.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

## 6.3 GlaxoSmithKline

6.3.1 Company Basic Information, Manufacturing Base and Competitors

6.3.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

## 6.4 Novartis

6.4.1 Company Basic Information, Manufacturing Base and Competitors

6.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

## 6.5 United Therapeutics

6.5.1 Company Basic Information, Manufacturing Base and Competitors

6.5.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and



## Specification

### 6.5.2.1 Product A

### 6.5.2.2 Product B

6.5.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

### 6.5.4 Main Business/Business Overview

## 6.6 AADi

6.6.1 Company Basic Information, Manufacturing Base and Competitors

6.6.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification

### 6.6.2.1 Product A

### 6.6.2.2 Product B

6.6.3 AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

### 6.6.4 Main Business/Business Overview

## 6.7 Actelion Pharmaceuticals

6.7.1 Company Basic Information, Manufacturing Base and Competitors

6.7.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification

### 6.7.2.1 Product A

### 6.7.2.2 Product B

6.7.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

### 6.7.4 Main Business/Business Overview

## 6.8 Aires Pharmaceuticals

6.8.1 Company Basic Information, Manufacturing Base and Competitors

6.8.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification

### 6.8.2.1 Product A

### 6.8.2.2 Product B

6.8.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

### 6.8.4 Main Business/Business Overview

## 6.9 Arena Pharmaceuticals

6.9.1 Company Basic Information, Manufacturing Base and Competitors

6.9.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification

### 6.9.2.1 Product A

### 6.9.2.2 Product B

6.9.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.9.4 Main Business/Business Overview

6.10 Asklepion Pharmaceuticals

6.10.1 Company Basic Information, Manufacturing Base and Competitors

6.10.2 Pulmonary Arterial Hypertension (PAH) Drugs Product Type, Application and Specification

6.10.2.1 Product A

6.10.2.2 Product B

6.10.3 Asklepion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.10.4 Main Business/Business Overview

6.11 AstraZeneca

6.12 Bayer Healthcare

6.13 Berlin Cures

6.14 BIAL

6.15 Eiger BioPharmaceuticals

## **7 PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MANUFACTURING COST ANALYSIS**

7.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs

## **8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

8.1 Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Drugs Major Manufacturers in 2016

8.4 Downstream Buyers

## **9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS**

- 9.1 Marketing Channel
  - 9.1.1 Direct Marketing
  - 9.1.2 Indirect Marketing
  - 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
  - 9.2.1 Pricing Strategy
  - 9.2.2 Brand Strategy
  - 9.2.3 Target Client
- 9.3 Distributors/Traders List

## **10 MARKET EFFECT FACTORS ANALYSIS**

- 10.1 Technology Progress/Risk
  - 10.1.1 Substitutes Threat
  - 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

## **11 EMEA PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET FORECAST (2017-2022)**

- 11.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Price Forecast (2017-2022)
  - 11.1.1 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate Forecast (2017-2022)
  - 11.1.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate Forecast (2017-2022)
  - 11.1.3 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Price and Trend Forecast (2017-2022)
- 11.2 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.4 Middle Eastt Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
- 11.5 Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Growth

Rate Forecast by Region (2017-2022)

11.6 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Type (2017-2022)

11.7 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Application (2017-2022)

## **12 RESEARCH FINDINGS AND CONCLUSION**

## **13 APPENDIX**

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

## List Of Tables

### LIST OF TABLES AND FIGURES

- Figure Product Picture of Pulmonary Arterial Hypertension (PAH) Drugs
- Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) by Type (2012-2022)
- Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Market Share by Type (Product Category) in 2016
- Figure Inhalation Product Picture
- Figure Injectables Product Picture
- Figure Oral administration Product Picture
- Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) by Application (2012-2022)
- Figure EMEA Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application in 2016
- Figure ERAs Examples
- Figure Prostacyclin analogs Examples
- Figure PDE inhibitors Examples
- Figure sGC stimulators Examples
- Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Million USD) by Region (2012-2022)
- Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Status and Forecast by Countries
- Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Status and Forecast by Countries
- Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Status and Forecast by Countries
- Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume and Growth Rate (2012-2022)
- Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Major Players

Product Sales Volume (K Units) (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) of Major Players (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players (2012-2017)

Figure 2016 Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players

Figure 2017 Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Players

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Market Major Players

Product Revenue (Million USD) (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Players (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players (2012-2017)

Table 2016 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players

Table 2017 EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Players

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sale Price (USD/Unit) by Players (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Market Share by Type (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2012-2017)

Figure Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Type (2012-2017)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Type in 2016

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sale Price (USD/Unit) by Type (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Market Share by Application (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2012-2017)

Figure Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Application (2012-2017)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2016

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Market Share by Region (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Region (2012-2017)

Figure Sales Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Region (2012-2017)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in 2016

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Region (2012-2017)

Figure Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Drugs by Region (2012-2017)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Regions in 2016

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Price (USD/Unit) by Region (2012-2017)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate (2012-2017)

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Type (2012-2017)

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type (2012-2017)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type in 2016

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Application (2012-2017)

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application (2012-2017)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2016

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by

Countries (2012-2017)

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries (2012-2017)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries (2012-2017)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries in 2016

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Countries (2012-2017)

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries in 2016

Figure Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure France Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure UK Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Benelux Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2017)

Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Type (2012-2017)

Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type (2012-2017)

Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type (2012-2017)

Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Applications (2012-2017)



Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Applications (2012-2017)

Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2016

Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) by Countries (2012-2017)

Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Market Share by Countries (2012-2017)

Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume Market Share by Countries in 2016

Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Countries (2012-2017)

Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries in 2016

Figure Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Israel Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure UAE Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Iran Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) and Growth Rate (2012-2017)

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by Type (2012-2017)

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2012-2017)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2012-2017)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2016

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) by

Application (2012-2017)

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2012-2017)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2012-2017)

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Volume (K Units) by Countries (2012-2017)

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries (2012-2017)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries (2012-2017)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Countries in 2016

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) by Countries (2012-2017)

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries (2012-2017)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Countries in 2016

Figure South Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Nigeria Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Algeria Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure DAIICHI SANKYO Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Novartis Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table AADi Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure AADi Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate (2012-2017)

Figure Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in EMEA (2012-2017)

Figure Asklepiion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share in EMEA (2012-2017)

Table AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table BIAL Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH) Drugs

Figure Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Drugs

Figure Pulmonary Arterial Hypertension (PAH) Drugs Industrial Chain Analysis

Table Raw Materials Sources of Pulmonary Arterial Hypertension (PAH) Drugs Major Manufacturers in 2016

Table Major Buyers of Pulmonary Arterial Hypertension (PAH) Drugs

Table Distributors/Traders List

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) and Growth Rate Forecast (2017-2022)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Growth Rate Forecast (2017-2022)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Unit) and Trend Forecast (2017-2022)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Region (2017-2022)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Region (2017-2022)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD)

Forecast by Region (2017-2022)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share

Forecast by Region (2017-2022)

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Countries (2017-2022)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Countries (2017-2022)

Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Middle East Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Countries (2017-2022)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Countries (2017-2022)

Table Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Countries (2017-2022)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Type (2017-2022)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Type (2017-2022)

Table EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Units) Forecast by Application (2017-2022)

Figure EMEA Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Application (2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

## Table Key Data Information from Primary Sources

## I would like to order

Product name: EMEA (Europe, Middle East and Africa) Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2017

Product link: <https://marketpublishers.com/r/E2478E83ACCEN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E2478E83ACCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



